Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pomalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 18/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 17/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | IL1B | P01584 | 2/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomalidomide SCHEMBL29382107 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930059 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930061 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL19250920 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525239 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525246 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525238 | 0.99 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15005 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4744680-A1 | TARGETED CHEMICAL DRUG AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE OF TARGETED CHEMICAL DRUG | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122059934-A | PD-L1 protein degradation targeting chimeric and preparation method and application thereof | 首都医科大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| EP-1285916-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2003-02-26 | — | — | EP | claimed |
| EP-0925294-B1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | claimed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | claimed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | claimed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | claimed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | claimed |